ERBB2 and breast carcinoma: The in vitro cytotoxicity of the same showed the lowest IC50 value, which suggests the increase in therapeutic efficacy in HER2 overexpressed human breast cancer and hence developed a promising strategy for HER2- overexpressed breast cancer [40].